NOVO NORDISK: Tirzepatide, not a major step forward | NEUTRAL | DK
NOVO NORDISK - NEUTRAL | DKK462(+10%)Tirzepatide, not a major step forward
Tirzepatide, a well-identified threat to Novo’s leadership in GLP1s
SURPASS-1 suggests tirzepatide is unlikely to move the lines
Novo-Nordisk is able to compete
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.